Process for producing engineered targeted T cell and medicine
US9205111B2 · kind B2 · utility
3Cited by
2References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 22, 2004 |
| Grant date | Dec 8, 2015 |
| Priority date | — |
| Expiry date | Aug 4, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N15/85
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A novel process for preparing tumor-specific T cells is disclosed. According to the invention, antitumor-active, tumor-specific T cells are prepared by transducing a TCR gene from a tumor-specific CTL into antitumor-active T cells that have been nonspecifically activated, thus enabling tumor-specific cellular immunotherapy to be carried out from even small amounts of blood. MHC class I-restricted, tumor-specific Th cells are obtained by the method, allowing for the production of cells that react with tumor cells expressing an MHC class I molecule and show a helper activity and an antitumor activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.